This position statement highlights the 'East Asian Paradox' of increased bleeding and reduced anti-ischemic benefit with potent antithrombotics, calling for tailored strategies in this population.
East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.
Kim et al. (Tue,) studied this question.